BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31464604)

  • 1. Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study.
    Sollie S; Michaud DS; Sarker D; Karagiannis SN; Josephs DH; Hammar N; Santaolalla A; Walldius G; Garmo H; Holmberg L; Jungner I; Van Hemelrijck M
    BMC Cancer; 2019 Aug; 19(1):858. PubMed ID: 31464604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum inflammatory markers and colorectal cancer risk and survival.
    Ghuman S; Van Hemelrijck M; Garmo H; Holmberg L; Malmström H; Lambe M; Hammar N; Walldius G; Jungner I; Wulaningsih W
    Br J Cancer; 2017 May; 116(10):1358-1365. PubMed ID: 28376082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between serum markers of the humoral immune system and inflammation in the Swedish AMORIS study.
    Santaolalla A; Sollie S; Rislan A; Josephs DH; Hammar N; Walldius G; Garmo H; Karagiannis SN; Van Hemelrijck M
    BMC Immunol; 2021 Sep; 22(1):61. PubMed ID: 34488637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between levels of C-reactive protein and leukocytes and cancer: three repeated measurements in the Swedish AMORIS study.
    Van Hemelrijck M; Holmberg L; Garmo H; Hammar N; Walldius G; Binda E; Lambe M; Jungner I
    Cancer Epidemiol Biomarkers Prev; 2011 Mar; 20(3):428-37. PubMed ID: 21297038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study.
    Arthur R; Williams R; Garmo H; Holmberg L; Stattin P; Malmström H; Lambe M; Hammar N; Walldius G; Robinsson D; Jungner I; Van Hemelrijck M
    Int J Cancer; 2018 Jun; 142(11):2254-2262. PubMed ID: 29322512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid cancer risk in the Swedish AMORIS study: the role of inflammatory biomarkers in serum.
    Ghoshal A; Garmo H; Arthur R; Carroll P; Holmberg L; Hammar N; Jungner I; Malmström H; Lambe M; Walldius G; Van Hemelrijck M
    Oncotarget; 2018 Jan; 9(1):774-782. PubMed ID: 29416653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study.
    Sollie S; Santaolalla A; Michaud DS; Sarker D; Karagiannis SN; Josephs DH; Hammar N; Walldius G; Garmo H; Holmberg L; Jungner I; Van Hemelrijck M
    Front Oncol; 2020; 10():263. PubMed ID: 32185133
    [No Abstract]   [Full Text] [Related]  

  • 8. Inflammation marker and risk of pancreatic cancer: a nested case-control study within the EPIC cohort.
    Grote VA; Kaaks R; Nieters A; Tjønneland A; Halkjær J; Overvad K; Skjelbo Nielsen MR; Boutron-Ruault MC; Clavel-Chapelon F; Racine A; Teucher B; Becker S; Pischon T; Boeing H; Trichopoulou A; Cassapa C; Stratigakou V; Palli D; Krogh V; Tumino R; Vineis P; Panico S; Rodríguez L; Duell EJ; Sánchez MJ; Dorronsoro M; Navarro C; Gurrea AB; Siersema PD; Peeters PH; Ye W; Sund M; Lindkvist B; Johansen D; Khaw KT; Wareham N; Allen NE; Travis RC; Fedirko V; Jenab M; Michaud DS; Chuang SC; Romaguera D; Bueno-de-Mesquita HB; Rohrmann S
    Br J Cancer; 2012 May; 106(11):1866-74. PubMed ID: 22617158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammatory plasma markers and pancreatic cancer risk: a prospective study of five U.S. cohorts.
    Bao Y; Giovannucci EL; Kraft P; Qian ZR; Wu C; Ogino S; Gaziano JM; Stampfer MJ; Ma J; Buring JE; Sesso HD; Lee IM; Rifai N; Pollak MN; Jiao L; Lessin L; Cochrane BB; Manson JE; Fuchs CS; Wolpin BM
    Cancer Epidemiol Biomarkers Prev; 2013 May; 22(5):855-61. PubMed ID: 23462920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron metabolism and risk of cancer in the Swedish AMORIS study.
    Gaur A; Collins H; Wulaningsih W; Holmberg L; Garmo H; Hammar N; Walldius G; Jungner I; Van Hemelrijck M
    Cancer Causes Control; 2013 Jul; 24(7):1393-402. PubMed ID: 23649231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3.
    Haas M; Kern C; Kruger S; Michl M; Modest DP; Giessen C; Schulz C; von Einem JC; Ormanns S; Laubender RP; Holdenrieder S; Heinemann V; Boeck S
    Tumour Biol; 2015 Apr; 36(4):2631-40. PubMed ID: 25472579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum biomarkers to predict risk of testicular and penile cancer in AMORIS.
    Ghoshal A; Garmo H; Arthur R; Hammar N; Jungner I; Malmström H; Lambe M; Walldius G; Hemelrijck MV
    Ecancermedicalscience; 2017; 11():762. PubMed ID: 28900475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer.
    Pine SR; Mechanic LE; Enewold L; Chaturvedi AK; Katki HA; Zheng YL; Bowman ED; Engels EA; Caporaso NE; Harris CC
    J Natl Cancer Inst; 2011 Jul; 103(14):1112-22. PubMed ID: 21685357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediagnostic serum inflammatory markers in relation to breast cancer risk, severity at diagnosis and survival in breast cancer patients.
    Wulaningsih W; Holmberg L; Garmo H; Malmstrom H; Lambe M; Hammar N; Walldius G; Jungner I; Van Hemelrijck M
    Carcinogenesis; 2015 Oct; 36(10):1121-8. PubMed ID: 26130675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mass spectrometric assay for analysis of haptoglobin fucosylation in pancreatic cancer.
    Lin Z; Simeone DM; Anderson MA; Brand RE; Xie X; Shedden KA; Ruffin MT; Lubman DM
    J Proteome Res; 2011 May; 10(5):2602-11. PubMed ID: 21417406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of head and neck cancer in relation to blood inflammatory biomarkers in the Swedish AMORIS cohort.
    Yang Y; Liang Y; Sadeghi F; Feychting M; Hamar N; Fang F; Zhang Z; Liu Q
    Front Immunol; 2023; 14():1265406. PubMed ID: 37876941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer.
    Chen IM; Johansen AZ; Dehlendorff C; Jensen BV; Bojesen SE; Pfeiffer P; Bjerregaard JK; Nielsen SE; Andersen F; Holländer NH; Yilmaz MK; Rasmussen LS; Johansen JS
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):176-184. PubMed ID: 31685562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic inflammation and risk of lung cancer in older adults in the health, aging and body composition cohort study.
    Demb J; Wei EK; Izano M; Kritchevsky S; Swede H; Newman AB; Shlipak M; Akinyemiju T; Gregorich S; Braithwaite D
    J Geriatr Oncol; 2019 Mar; 10(2):265-271. PubMed ID: 30078713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory serum markers and risk and severity of prostate cancer: The PROCA-life study.
    Stikbakke E; Richardsen E; Knutsen T; Wilsgaard T; Giovannucci EL; McTiernan A; Eggen AE; Haugnes HS; Thune I
    Int J Cancer; 2020 Jul; 147(1):84-92. PubMed ID: 31583707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical usefulness of postoperative C-reactive protein/albumin ratio in pancreatic ductal adenocarcinoma.
    Arima K; Yamashita YI; Hashimoto D; Nakagawa S; Umezaki N; Yamao T; Tsukamoto M; Kitano Y; Yamamura K; Miyata T; Okabe H; Ishimoto T; Imai K; Chikamoto A; Baba H
    Am J Surg; 2018 Jul; 216(1):111-115. PubMed ID: 28859917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.